Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ari Zimran

Showing results (211-220 of 238) with videos related to

Pageof 24
Sort By:
American Journal of Hematology|March 25, 2015
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trialsDerralynn A Hughes, Derlis E Gonzalez, Elena A Lukina, et al.
Plos One|November 27, 2013
Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patientsArndt Rolfs, Anne-Katrin Giese, Ulrike Grittner, et al.
Skeletal Radiology|May 13, 2014
Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustatRavi S Kamath, Elena Lukina, Nora Watman, et al.
British Journal of Haematology|May 30, 2012
Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 yearsCarla E M Hollak, Nadia Belmatoug, J Alexander Cole, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 23, 2009
A validated disease severity scoring system for adults with type 1 Gaucher diseaseNeal J Weinreb, Maria D Cappellini, Timothy M Cox, et al.
International Journal of Molecular Sciences|July 13, 2024
<i>GBA1</i>-Associated Parkinson's Disease Is a Distinct EntityAliaksandr Skrahin, Mia Horowitz, Majdolen Istaiti, et al.
American Journal of Hematology|May 14, 2016
Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher diseaseAri Zimran, Gloria Durán, Atul Mehta, et al.
JAMA Neurology|April 24, 2014
Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotesRoy N Alcalay, Tama Dinur, Timothy Quinn, et al.
Archives of Internal Medicine|February 13, 2008
Prevalence of type 1 Gaucher disease in the United StatesNeal J Weinreb, Hans C Andersson, Maryam Banikazemi, et al.
Orphanet Journal of Rare Diseases|January 7, 2022
Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trialsDeborah Elstein, Nadia Belmatoug, Patrick Deegan, et al.
Pageof 24

Showing results (211-220 of 238) with videos related to

Sort By:
Pageof 24
American Journal of Hematology|March 25, 2015
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trialsDerralynn A Hughes, Derlis E Gonzalez, Elena A Lukina, et al.
Plos One|November 27, 2013
Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patientsArndt Rolfs, Anne-Katrin Giese, Ulrike Grittner, et al.
Skeletal Radiology|May 13, 2014
Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustatRavi S Kamath, Elena Lukina, Nora Watman, et al.
British Journal of Haematology|May 30, 2012
Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 yearsCarla E M Hollak, Nadia Belmatoug, J Alexander Cole, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 23, 2009
A validated disease severity scoring system for adults with type 1 Gaucher diseaseNeal J Weinreb, Maria D Cappellini, Timothy M Cox, et al.
International Journal of Molecular Sciences|July 13, 2024
<i>GBA1</i>-Associated Parkinson's Disease Is a Distinct EntityAliaksandr Skrahin, Mia Horowitz, Majdolen Istaiti, et al.
American Journal of Hematology|May 14, 2016
Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher diseaseAri Zimran, Gloria Durán, Atul Mehta, et al.
JAMA Neurology|April 24, 2014
Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotesRoy N Alcalay, Tama Dinur, Timothy Quinn, et al.
Archives of Internal Medicine|February 13, 2008
Prevalence of type 1 Gaucher disease in the United StatesNeal J Weinreb, Hans C Andersson, Maryam Banikazemi, et al.
Orphanet Journal of Rare Diseases|January 7, 2022
Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trialsDeborah Elstein, Nadia Belmatoug, Patrick Deegan, et al.
Pageof 24